Acurx Pharmaceuticals Reveals DNA pol IIIC Inhibitors Results at LED3 Conference

Acurx Pharmaceuticals Announcements at the LED3 Conference

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a prominent biopharmaceutical firm, has made significant strides in the field of antimicrobial treatments with its DNA pol IIIC inhibitors. Recently, at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference, the company presented groundbreaking results from its ongoing collaboration with the Leiden University Medical Center (LUMC).

The presentation, delivered by Dr. Mia Urem of LUMC, was titled "A unique inhibitor conformation selectively targets Gram+ Bacterial DNA Replication." The findings underscore the company’s commitment to tackling difficult-to-treat bacterial infections, particularly those caused by Gram-positive bacteria. Using advanced cryo-electron microscopy, the team elucidated the structure of ibezapolstat, a novel antibiotic, and its interaction with bacterial DNA polymerase IIIC, reaching a remarkable resolution of 3.2Å.

Highlights from the Presentation

The research revealed that the structure of ibezapolstat strategically binds to the active site of the DNA polymerase IIIC enzyme, a critical component conserved across over 220 Gram-positive species. This suggests that Acurx’s compounds could have broad clinical utility and further enhance treatment options for various multi-drug resistant infections. Dr. Wiep Klaas Smits, a principal investigator at LUMC, emphasized that the insights into the structural biology of DNA pol IIIC have vast implications for developing new antibiotics aimed at high-priority, resistant Gram-positive infections.

Acurx's Executive Chairman, Bob DeLuccia, also touched on the importance of this research in understanding how ibezapolstat interacts with gut microbiota. This knowledge will inform the rational design of future compounds which could possess improved antimicrobial properties. The ability of their compounds to selectively target pathogenic bacteria while preserving beneficial gut flora is especially critical given the rising threat of antimicrobial resistance globally.

The Road Ahead

Acurx is positioned to advance ibezapolstat into international Phase 3 clinical trials for treating Clostridioides difficile infections (CDI), which are a significant public health concern. CDI is responsible for approximately 500,000 infections yearly in the U.S., leading to tens of thousands of deaths. The Phase 3 trials will assess ibezapolstat's efficacy compared to the standard treatment of vancomycin, potentially paving the way for approved new treatments in a field that desperately needs them.

In addition to CDI, Acurx's research pipeline includes candidates targeting other challenging infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and other drug-resistant pathogens. This wide-ranging focus illustrates the company's dedication to resolving the ongoing crisis of antimicrobial resistance, informed by collaborations like the one with LUMC.

The collaboration with LUMC is part of a public-private partnership funded, in part, by Health Holland, aimed at fostering innovative research in life sciences. The merging of academic expertise with biopharmaceutical know-how empowers Acurx to foster groundbreaking research and development around antimicrobial therapies.

Conclusion

As Acurx Pharmaceuticals prepares to enter the next phase of clinical trials, their relentless pursuit of novel antibiotics represents a beacon of hope in the fight against antimicrobial resistance. Their latest findings at the LED3 conference not only mark a significant step for Acurx but also offer insights that could reshape the treatment landscape for bacterial infections globally. The path carved by Acurx may prove crucial in ensuring effective therapies are developed to meet the pressing healthcare challenges posed by resistant bacterial strains.